Hassan FILALI

Conference 2023 Live Talk

Talk title

Authors and Affiliations

Hassan FILALI1, Mohamed ouadie Yaacoubi1, Ayoub LAHMADI1, Asmaa QUESSAR2, Souad ABOUDKHIL1

1. Laboratory of Biochemistry, Environment and Agrifood (URAC 36) Faculty of Science and Technology Mohammedia-
University Hassan II of Casablanca – Morocco
2. Hematology and Pediatric Oncology Service-Hospital August 20 University Hospital Center IBN ROCHD Casablanca- Morocco

Abstract

Background

The proteasome is a proteolytic complex for intracellular degradation of ubiquitinated proteins which are involved in cell-cycle regulation, DNA repair, apoptosis (p53 and Caspase) angiogenesis (VEGF), inflammation (NF-kB, IL6 ….) immune response (antigen presentation) (filali et al,2022).

Methods

Methodology: Quantitative and functional analysis of the proteasome was conducted at the subcellular level and serum during a pathological phenomenon in 145 Moroccan patients (sex ratio: 1.10 / average age: 47.9 ± 15.3 years) with ELISA assay, and by following the fluorescence emitted after enzymatic digestion of specific peptides by the chymotrypsin-like activity.

Results

This work focused on a study in a large cohort of patients with Moroccan Hematologic malignancies in order to follow the evolution of the 20S proteasome in serum and intracellular according to clinical status. A constitutively increased proteasome activity has been found in myeloma cells.
Serum proteasome concentrations were significantly elevated in MM compared with controls (P < .001). In patients with active MM, there was a significant (P < .001) decrease from pretreatment to post-treatment proteasome concentrations in responders to chemotherapy. the entire population of 60 patients reported a significant drop in the rate and the activity of the proteasome in serum and intracellular level.

Conclusions

The evolutionary trend of subcellular proteasome is significantly linked to the rate of chymotrypsin-like activity.
The use of proteasome circulating assay as a biomarker of tumor and a tool that could be very satisfying to follow patients after remission to prevent a possible fall.
The evolutionary trend of subcellular proteasome is significantly linked to the rate of chymotrypsin-like activity.
The use of proteasome circulating assay as a biomarker of tumor and a tool that could be very satisfying to follow patients after remission to prevent a possible fall.